Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia

Hepatology Research

Volumn 45, Issue 12, 2015, Pages 1155-1162

  Iwasa, Motoh ^a   Takei, Yoshiyuki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Astrocyte; Brain edema; Cirrhosis; Hepatic encephalopathy; Hyperammonemia; Hyponatremia

Indexed keywords

AMMONIA; BRANCHED CHAIN AMINO ACID; C REACTIVE PROTEIN; CARNITINE; GLUTAMATE AMMONIA LIGASE; GLUTAMINE; INOSITOL; INTERLEUKIN 6; KANAMYCIN; LACTITOL; LACTULOSE; ORNITHINE ASPARTATE; POLYMYXIN B; PREBIOTIC AGENT; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; RIFAXIMIN; SATAVAPTAN; SYNBIOTIC AGENT; TOLVAPTAN; VASOPRESSIN V2 RECEPTOR;

ASCITES; ASTROCYTE; BLOATING; BRAIN EDEMA; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ENTERIC FEEDING; ENTEROCOLITIS; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; HYPONATREMIA; INFECTION; INTESTINE FLORA; LIVER CIRRHOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOTIC PRESSURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN RESTRICTION; QUALITY OF LIFE; REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UNSPECIFIED SIDE EFFECT; VOXEL BASED MORPHOMETRY;

EID: 84988293811     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12495     Document Type: Review

References (57)

1. Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther 2012; 92: 321-31.
2. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-65.
3. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515-25.
4. Butterworth RF. Pathophysiology of hepatic encephalopathy: The concept of synergism. Hepatol Res 2008; 38: S116-21.
5. Angeli P, Wong F, Watson H, Ginès P. CAPPS Investigators. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006; 44: 1535-42.
6. Ginès P, Guevara M. Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. Hepatology 2008; 48: 1002-10.
7. Solà E, Watson H, Graupera I et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol 2012; 57: 1199-206.
8. Heins J, Zwingmann C. Organic osmolytes in hyponatremia and ammonia toxicity. Metab Brain Dis 2010; 25: 81-9.
9. Córdoba J, García-Martinez R, Simón-Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence. Metab Brain Dis 2010; 25: 73-80.
10. Bass NM, Mullen KD, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-81.
11. Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: A meta-analysis. World J Gastroenterol 2012; 18: 767-77.
12. Sakaida I, Kawazoe S, Kajimura K et al. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 2014; 44: 73-82.
13. Cooper AJ, Plum F. Biochemistry and physiology of brain ammonia. Physiol Rev 1987; 67: 440-519.
14. Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000; 32: 1035-8.
15. Rose C, Kresse W, Kettenmann H. Acute insult of ammonia leads to calcium-dependent glutamate release from cultured astrocytes, an effect of pH. J Biol Chem 2005; 280: 20937-44.
16. Córdoba J, Sanpedro F, Alonso J, Rovira A. 1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis 2002; 17: 415-29.
17. Häussinger D, Laubenberger J, vom Dahl S et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 1994; 107: 1475-80.
18. Iwasa M, Mifuji-Moroka R, Kuroda M et al. Regional reduction in gray and white matter volume in brains of cirrhotic patients: Voxel-based analysis of MRI. Metab Brain Dis 2012; 27: 551-7.
19. Sugimoto R, Iwasa M, Maeda M et al. Value of the apparent diffusion coefficient for quantification of low-grade hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1413-20.
20. Iwasa M, Kinosada Y, Nakatsuka A, Watanabe S, Adachi Y. Magnetization transfer contrast of various regions of the brain in liver cirrhosis. AJNR Am J Neuroradiol 1999; 20: 652-4.
21. Babington JR, Stahl JH, Coy DL. Reversible cytotoxic edema in a cirrhotic patient following TIPS. J Neuroimaging 2009; 19: 391-3.
22. Kavitt RT, Yang VL, Jensen DM. Cerebral edema and hyperammonemia after transjugular intrahepatic portosystemic shunt placement in a cirrhotic patient. Clin Gastroenterol Hepatol 2008; 6: 1054-6.
23. Mardini H, Smith FE, Record CO, Blamire AM. Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia. J Hepatol 2011; 54: 1154-60.
24. Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007; 22: 125-38.
25. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40: 247-54.
26. Murthy CR, Rama Rao KV, Bai G, Norenberg MD. Ammonia-induced production of free radicals in primary cultures of rat astrocytes. J Neurosci Res 2001; 66: 282-8.
27. Frederick RT. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol (N Y) 2011; 7: 222-33.
28. Förster A, Nölte I, Wenz H et al. Value of diffusion-weighted imaging in central pontine and extrapontine myelinolysis. Neuroradiology 2013; 55: 49-56.
29. Guevara M, Baccaro ME, Torre A et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: A prospective study with time-dependent analysis. Am J Gastroenterol 2009; 104: 1382-9.
30. Iwasa M, Sugimoto R, Takei Y. Patients with hyponatremic cirrhosis have low-grade cerebral edema and poor quality-of-life. Ann Hepatol 2014; 13: 407-8.
31. Amodio P, Del Piccolo F, Pettenò E et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 2001; 35: 37-45.
32. Jalan R, Elton RA, Redhead DN, Finlayson ND, Hayes PC. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J Hepatol 1995; 23: 123-8.
33. Guevara M, Baccaro ME, Ríos J et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int 2010; 30: 1137-42.
34. Kato A, Tanaka H, Kawaguchi T et al. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study. Hepatol Res 2013; 43: 452-8.
35. Ahluwalia V, Wade JB, Thacker L et al. Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol 2013; 59: 467-73.
36. Marchesini G, Bianchi G, Rossi B, Brizi M, Melchionda N. Nutritional treatment with branched-chain amino acids in advanced liver cirrhosis. J Gastroenterol 2000; 35: 7-12.
37. Iwasa M, Iwata K, Hara N et al. Nutrition therapy using a multidisciplinary team improves survival rates in patients with liver cirrhosis. Nutrition 2013; 29: 1418-21.
38. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046.
39. Teperman LW, Peyregne VP. Considerations on the impact of hepatic encephalopathy treatments in the pretransplant setting. Transplantation 2010; 89: 771-8.
40. Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010; 31: 1012-7.
41. Bajaj JS, Heuman DM, Sanyal AJ et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8: e60042.
42. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-5.
43. Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther 2012; 3: 62-7.
44. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012; 55: 1164-71.
45. Marchesini G, Bianchi G, Merli M et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: A double-blind, randomized trial. Gastroenterology 2003; 124: 1792-801.
46. Kawaguchi T, Taniguchi E, Sata M. Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis. Nutr Clin Pract 2013; 28: 580-8.
47. Marchesini G, Dioguardi FS, Bianchi GP et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990; 11: 92-101.
48. Gluud LL, Dam G, Borre M et al. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr 2013; 143: 1263-8.
49. Dam G, Keiding S, Munk OL et al. Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. Am J Physiol Gastrointest Liver Physiol 2011; 301: G269-77.
50. Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis 2013; 28: 193-9.
51. Cooper AJ. Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase. Metab Brain Dis 2013; 28: 119-25.
52. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108: 1458-63.
53. Malaguarnera M, Risino C, Cammalleri L et al. Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. Eur J Gastroenterol Hepatol 2009; 21: 762-70.
54. Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 2011; 33: 662-71.
55. Bajaj JS, Heuman DM, Hylemon PB et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60: 940-7.
56. Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 2014; 12: 1003-8.
57. Dahl E, Gluud LL, Kimer N, Krag A. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther 2012; 36: 619-26.